These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 18219840

  • 1. Myocardial infarction during intravenous immunoglobulin infusion in a 65-year-old man with common variable immunodeficiency and subsequent successful repeated administration.
    Davé S, Hagan J.
    Ann Allergy Asthma Immunol; 2007 Dec; 99(6):567-70. PubMed ID: 18219840
    [Abstract] [Full Text] [Related]

  • 2. Acute ST elevation myocardial infarction during intravenous immunoglobulin infusion.
    Barsheshet A, Marai I, Appel S, Zimlichman E.
    Ann N Y Acad Sci; 2007 Sep; 1110():315-8. PubMed ID: 17911446
    [Abstract] [Full Text] [Related]

  • 3. A case of common variable immunodeficiency syndrome associated with Takayasu arteritis.
    Jerschow E, De Vos GS, Hudes G, Rubinstein A, Lipsitz EC, Rosenstreich D.
    Ann Allergy Asthma Immunol; 2007 Feb; 98(2):196-9. PubMed ID: 17304891
    [Abstract] [Full Text] [Related]

  • 4. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.
    Marie I, Maurey G, Hervé F, Hellot MF, Levesque H.
    Br J Dermatol; 2006 Oct; 155(4):714-21. PubMed ID: 16965420
    [Abstract] [Full Text] [Related]

  • 5. Serum IgG subclass concentrations before and after administration of intravenous immunoglobulin in common variable immunodeficiency.
    Ozawa T, Motoyoshi F, Kato Y, Kondo N, Orii T.
    J Clin Lab Immunol; 1992 Oct; 38(1):29-39. PubMed ID: 1343346
    [Abstract] [Full Text] [Related]

  • 6. [Personal experience with replacement therapy with intravenous gamma globulin].
    Litzman J, Lokaj J, Stikarovská D, Mayer J, Thon V, Eibl MM.
    Vnitr Lek; 1995 Nov; 41(11):759-63. PubMed ID: 8553594
    [Abstract] [Full Text] [Related]

  • 7. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency.
    Pourpak Z, Aghamohammadi A, Sedighipour L, Farhoudi A, Movahedi M, Gharagozlou M, Chavoshzadeh Z, Jadid L, Rezaei N, Moin M.
    J Microbiol Immunol Infect; 2006 Apr; 39(2):114-20. PubMed ID: 16604243
    [Abstract] [Full Text] [Related]

  • 8. Subcutaneous immunoglobulin therapy in an 11-year-old patient with common variable immunodeficiency and von Willebrand disease.
    Arora R, Newton TC, Nelson MR.
    Ann Allergy Asthma Immunol; 2007 Oct; 99(4):367-70. PubMed ID: 17941286
    [Abstract] [Full Text] [Related]

  • 9. Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non-respiratory infections in common variable immune deficiency.
    Favre O, Leimgruber A, Nicole A, Spertini F.
    Allergy; 2005 Mar; 60(3):385-90. PubMed ID: 15679727
    [Abstract] [Full Text] [Related]

  • 10. Intravenous immunoglobulin, blood viscosity and myocardial infarction.
    Fisman DN, Smilovitch M.
    Can J Cardiol; 1997 Aug; 13(8):775-7. PubMed ID: 9284845
    [Abstract] [Full Text] [Related]

  • 11. The impact of B-type natriuretic peptide in addition to troponin I, creatine kinase-MB, and myoglobin on the risk stratification of emergency department chest pain patients with potential acute coronary syndrome.
    Brown AM, Sease KL, Robey JL, Shofer FS, Hollander JE.
    Ann Emerg Med; 2007 Feb; 49(2):153-63. PubMed ID: 17084941
    [Abstract] [Full Text] [Related]

  • 12. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
    Gürcan HM, Ahmed AR.
    Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Safety of intravenous immunoglobulin (IVIG) therapy.
    Katz U, Achiron A, Sherer Y, Shoenfeld Y.
    Autoimmun Rev; 2007 Mar; 6(4):257-9. PubMed ID: 17317619
    [Abstract] [Full Text] [Related]

  • 15. Effects of intravenous immunoglobulin on clinical and immunological findings of patients with humoral immunodeficiency diseases.
    Ersoy F, Tezcan I, Sanal O.
    Turk J Pediatr; 1992 Mar; 34(4):203-9. PubMed ID: 1306339
    [Abstract] [Full Text] [Related]

  • 16. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation.
    Chapman SA, Gilkerson KL, Davin TD, Pritzker MR.
    Ann Pharmacother; 2004 Dec; 38(12):2059-67. PubMed ID: 15536143
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Quality of life in common variable immunodeficiency requiring intravenous immunoglobulin therapy.
    Tcheurekdjian H, Palermo T, Hostoffer R.
    Ann Allergy Asthma Immunol; 2004 Aug; 93(2):160-5. PubMed ID: 15328676
    [Abstract] [Full Text] [Related]

  • 19. Effect of IVIG on the hair regrowth in a common variable immune deficiency patient with alopecia universalis.
    Boonyaleepun S, Boonyaleepun C, Schlactus JL.
    Asian Pac J Allergy Immunol; 1999 Mar; 17(1):59-62. PubMed ID: 10403010
    [Abstract] [Full Text] [Related]

  • 20. Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases.
    Mignogna MD, Fortuna G, Leuci S, Ruoppo E, Adamo D, Fedele S.
    Clin Exp Dermatol; 2009 Mar; 34(2):145-50. PubMed ID: 19187294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.